AlphAIalphai — Financial news for AI agents
tradingview.comAUG 81 min read$BBIO

BridgeBio Oncology Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.89, Implies 167% Upside

Analyst estimates cited by FactSet show BridgeBio Oncology Therapeutics, Inc. average 12-month price target was cut to $24.89 from $25.30. The range is $18 to $41. Based on the Aug. 7 close, the target implies about 167% upside. Consensus remains “Buy” with 10 Buys and no Holds or Sells.

Original reporting
tradingview.com
Published Aug 8, 2026, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 3:06 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
BridgeBio Oncology Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.89, Implies 167% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

A lower average target reduces the implied upside reference point, but the unchanged Buy consensus suggests analysts still expect favorable risk-reward.

02

Market read

Valuation anchor shifts slightly lower while overall analyst stance remains Buy.

03

What to watch

The article provides no catalyst (no trial/regulatory/earnings update), so traders should treat this as sentiment/valuation housekeeping rather than a fundamental inflection.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session positioning based on analyst target change

Background

The piece summarizes FactSet-derived analyst estimates and consensus ratings for BridgeBio Oncology Therapeutics.

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

BridgeBio Oncology Therapeutics’ consensus average price target was cut from $25.30 to $24.89, with analyst forecasts spanning $18 to $41.

Expected impact

Near-term bias is likely mildly negative versus prior target levels, but the unchanged Buy consensus limits downside follow-through.

Evidence & confidence

A target cut can pressure sentiment, but the body also states consensus remains Buy (10 Buys, 0 Holds, 0 Sells), reducing the probability of a sharp repricing without additional new fundamentals.

Market effects

Sector

Limited read-through to biotech/oncology peers because the update is only a price-target revision, not new clinical or regulatory data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the market had already priced in the prior $25.30 target, the $24.89 cut may have little incremental impact, especially with the same Buy consensus.

Key entities

  • public_company
    BridgeBio Oncology Therapeutics, Inc.

    Subject of the article; average analyst price target cut to $24.89 with Buy consensus unchanged.

Read at source← All news

Related articles

AUG 11
$BBOTMed

BridgeBio Oncology Therapeutics, Inc. (BBOT): Results of Operations and Financial Condition

BridgeBio Oncology Therapeutics, Inc. (BBOT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bbot-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress • Continued to advance monotherapy and combination cohorts for all clinical programs • Initiated dosing of BBO-11818 in combination with cetu

SEC EDGAR 8-K4 min
AUG 10
$BBIOMedAI 8/10

[BBIO Q2 2026 Earnings Call] Attruby Sales Hit $222M, Surge 120%, as BridgeBio Maps ‘Launch 2.0’ with $1.7B War Chest — BigGo Finance

BridgeBio Pharma (BBIO) reported Q2 2026 Attruby net product revenue of $222.4M, up from $71.5M a year earlier, and total revenue up 120% to $243.7M. Management said it has $1.7B cash after a $1B preferred equity deal. The company discussed CARDIO-TTRansform failure, regulatory progress on three NDAs, and expects breakeven toward 2027.

finance.biggo.com7 min
AUG 10
$BBIOMedAI 8/10

BridgeBio Pharma, Inc. (BBIO): Results of Operations and Financial Condition

BridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bbio-20260630xex991.htm EX-99.1 Document Exhibit 99.1 BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth

SEC EDGAR 8-K7 min
JUL 23
$BBIOMedAI 8/10

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

BridgeBio Pharma (BBIO) said the FDA accepted its filing for encaleret, an oral investigational drug for autosomal dominant hypocalcemia type 1 (ADH1). A decision is expected by May 8, 2027. The company cited phase III CALIBRATE results and noted the FDA is not planning an advisory committee meeting. BBIO shares are up 8% YTD.

tradingview.com4 min
JUL 22
$BBIOMedAI 8/10

FDA accepts BridgeBio's NDA for encaleret to tr... | Pluang

BridgeBio Pharma said the FDA accepted its New Drug Application for encaleret, intended as a potential first treatment for autosomal dominant hypocalcemia type 1 (ADH1). The FDA target decision date is May 8, 2027. BridgeBio cited trial results showing efficacy and safety without routine calcium or vitamin D supplements, and is also studying pediatric ADH1 and chronic hypoparathyroidism.

pluang.com1 min